Summit Therapeutics is trading 13.44% higher at $17.56 after AstraZeneca agreed to invest $2 billion and collaborate on cancer-treatment trials. - The investment is priced at an effective $18.36 per common share. - The companies plan to test AstraZeneca’s sonesitatug vedotin with Summit’s ivonescimab in gastrointestinal cancers. - Reuters reported a 23% premarket rise; broader markets were comparatively subdued.